The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Evolution of Glucocorticoids

The Evolution of Glucocorticoids

February 12, 2011 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF

And yet, today, “discovery-driven research,” as these expeditions have now been relabeled, is acceptable. By applying discovery-driven methods, Dr. Chrousos and his colleagues have begun to uncover additional properties of GR signaling. He highlighted one such “expedition” begun 15 years ago, when he and his team decided to use pieces of the GR as “bait” to see what kinds of proteins would interact within the cell.

You Might Also Like
  • New Assay Aids In Evaluating Metabolic Effects of Glucocorticoids
  • Glucocorticoids a Fracture Risk at Any Dose
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
Explore This Issue
February 2011
Also By This Author
  • Early 2022’s Awards, Appointments & Announcements in Rheumatology

One of the most interesting things they found was that one component of the GR bound to the CLOCK transcription factor, an important molecule that regulates day and night activity of an organism. They also discovered that glucocorticoid actions are coupled to the body’s circadian rhythms. For example, the CLOCK transcription factor produces part of the 24-hour oscillations of the genome through altering the activity of the glucocorticoid receptor. Cortisol secretion is typically high at around 8 a.m., peaks again at lunchtime, and then decreases each evening. Examining 24-hour oscillations in the sensitivity of circulating white cells to glucocorticoids, Dr. Chrousos observed that their response to cortisol is an inverse one: In the morning, when cortisol levels are high, the body’s tissues are resistant to its effects. In the evening, when cortisol levels are low, tissues are hypersensitive.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are many examples of pathology due to the aberrant coupling of the CLOCK and the HPA axis, such as chronic stress, when the body is subjected to chronically high levels of endogenous cortisol, and in such diseases as Cushing’s disease. Likewise, in people who do night-shift work or travel across time zones frequently, the decoupling of CLOCK and the HPA axis can lead to functional hypercortisolism and serious health consequences, such as developing metabolic syndrome (possibly leading to diabetes mellitus type 2), atherosclerosis, and cardiovascular disease. These are just some of the ways by which glucocorticoids, when hypersecreted or hyperfunctional because of uncoupling with tissue sensitivity, can cause premature aging, collection of visceral fat, and loss of muscle.

Earlier, Dr. Chrousos used Hooke’s Law of Physics to illustrate the parallels between GR signaling and pressure exerted on metal. Just as with a metal rod, the body can withstand and bend with the “pressure” of dealing with stress hormones. For the most part, he noted, “we are resilient to perturbations.” But if the tipping point is crossed, returning to homeostasis will not be possible. Cacostasis ensues.5 We now know that glucocorticoid over- or under-secretion or, respectively, tissue hypersensitivity or resistance play significant roles in the genesis of many disorders, including metabolic syndrome, diabetes type II, inflammatory and allergic disorders, depression, and insomnia. Humans, according to Dr. Chrousos, consist of multiple systems self-organized into a whole. “And in complex systems, too much or too little is associated with poor performance; everything in moderation is very important.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Future Implications

At the conclusion of the lecture, moderator Steven R. Goldring, MD, of the Hospital for Special Surgery in New York City, said that given the different functions of the glucocorticoid receptors in different tissues, these might present an ideal system for developing selective glucocorticoid receptor modulators.

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates Tagged With: 2010 ACR/ARHP Annual Scientific Meeting, Glucocorticoids, Steroid, TreatmentIssue: February 2011

You Might Also Like:
  • New Assay Aids In Evaluating Metabolic Effects of Glucocorticoids
  • Glucocorticoids a Fracture Risk at Any Dose
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)